Colistin

Generic Name: Colistin

Brand Names: Cortisporin-TC

Drug Type: Small Molecule

Chemical Formula: C_₅₂H_₉₈N_₁₆O_₁₃

CAS Number: 1066-17-7

Unique Ingredient Identifier: Z67X93HJG1

Background: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

Indication: For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Associated Conditions: Ear infection bacterial, External ear infection NOS

Associated Therapies: -

Clinical Trials

Colistin Dosage Prsonalization Approach

Recruiting

Conditions: Colistin Adverse Reaction

Interventions: Drug: Polymyxin e

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Mahmoud I Mostafa

Target Recruit Count: 100

Registration Number: NCT06472271

Locations: 🇪🇬
Cairo univrsity Hospitals, Cairo, Egypt

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Phase 4

Not yet recruiting

Conditions: Carbapenem Resistant Bacterial Infection
Acinetobacter Bacteremia
Acinetobacter Pneumonia

Interventions: Drug: Cefiderocol
Drug: Colistin
Drug: Ampicillin-sulbactam
Drug: Meropenem

First Posted Date: 2023-06-28

Last Posted Date: 2024-04-16

Lead Sponsor: Rambam Health Care Campus

Target Recruit Count: 734

Registration Number: NCT05922124

Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Phase 3

Completed

Conditions: Secondary Bacterial Infection in COVID-19 Patients

Interventions: Drug: Colistin

First Posted Date: 2023-01-19

Last Posted Date: 2023-01-19

Lead Sponsor: Beni-Suef University

Target Recruit Count: 128

Registration Number: NCT05689229

Locations: 🇪🇬
University Hospital, Banī Suwayf, Beni-Suef, Egypt

The Effect of Curcumin Against Colistin-induced Nephrotoxicity

Phase 3

Recruiting

Conditions: Acute Kidney Injury
Drug-Induced Nephropathy

Interventions: Drug: Colistin
Drug: Curcumin

First Posted Date: 2022-11-14

Last Posted Date: 2023-10-31

Lead Sponsor: October 6 University

Target Recruit Count: 214

Registration Number: NCT05613361

Locations: 🇪🇬
Cairo University Hospitals, Cairo, Egypt

Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection

Phase 4

Recruiting

Conditions: Acinetobacter Infections

Interventions: Drug: Colistin
Drug: Placebo
Drug: Minocycline

First Posted Date: 2022-10-19

Last Posted Date: 2023-01-18

Lead Sponsor: Mahidol University

Target Recruit Count: 94

Registration Number: NCT05586815

Locations: 🇹🇭
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation

Phase 4

Terminated

Conditions: Colistin

Interventions: Drug: Colistin

First Posted Date: 2022-09-15

Last Posted Date: 2024-01-31

Lead Sponsor: St. Anne's University Hospital Brno, Czech Republic

Target Recruit Count: 8

Registration Number: NCT05542446

Locations: 🇨🇿
St. Anne's University Hospital Brno, Brno, Czech Republic, Czechia

Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients

Early Phase 1

Conditions: Hepatic Encephalopathy

Interventions: Drug: lactulose
Drug: colistin

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: Madonna Magdy Fahmy

Target Recruit Count: 316

Registration Number: NCT05279586

Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections

Phase 3

Terminated

Conditions: Carbapenem-Resistant Enterobacteriaceae Infection

Interventions: Drug: Ceftazidime-avibactam
Drug: Colistin

First Posted Date: 2022-02-28

Last Posted Date: 2024-06-14

Lead Sponsor: King Faisal Specialist Hospital & Research Center

Target Recruit Count: 29

Registration Number: NCT05258851

Locations: 🇸🇦
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.

Phase 4

Conditions: Multi-antibiotic Resistance
Critically Ill
Hospital Infection

Interventions: Drug: Colistin

First Posted Date: 2021-08-06

Last Posted Date: 2021-08-06

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 20

Registration Number: NCT04995133

Locations: 🇮🇹
Fondazione Policlinico A.Gemelli IRCSS, Roma, Italia, Italy

Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae

Phase 4

Conditions: Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae

Interventions: Drug: Colistin
Drug: Tigecycline
Drug: Meropenem

First Posted Date: 2020-07-28

Last Posted Date: 2020-07-29

Lead Sponsor: Al-Azhar University

Target Recruit Count: 60

Registration Number: NCT04489459

Locations: 🇪🇬
Qasr El Ainy, Cairo, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy